Not a good buy right now for an impatient trader: price is sitting at/just below near-term support (~1.309) with bearish momentum still accelerating (MACD histogram negative and expanding).
Oversold RSI (6) at ~18 can spark a dead-cat bounce, but there is no Intellectia buy signal and the broader trend is still down—odds favor chop/breakdown over a clean reversal.
Options positioning (low put/call ratios) is directionally bullish, but overall options activity is thin, so it’s not a strong confirmation signal.
Event catalyst (SomaLogic sale) is positive for cash, but recent fundamentals show steep revenue contraction; next major catalyst is earnings on 2026-03-02 (after hours).
Trend/Momentum: Bearish. MACD histogram -0.0299 (below 0) and negatively expanding suggests downside momentum is strengthening.
RSI: RSI_6 ~18.2 = deeply oversold (bounce risk), but oversold alone is not a reversal trigger.
Moving averages: Converging MAs suggest the stock is compressing after a decline; resolution risk remains to the downside given MACD.
Levels: Pre-market ~1.30 is right around S1=1.309 and above S2=1.214.
If 1.309 fails, downside opens toward ~1.214.
To look constructive, it needs to reclaim Pivot ~1.462, then R1 ~1.614.
Pattern-based expectation (given): modest edge at best (next day +1.54% with 50% probability; next week ~flat).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Bullish skew (OI put/call 0.32; essentially no put volume today), but note today’s total volume is very low (28 contracts), limiting signal quality.
Volatility: IV (30d) ~132.8% vs historical vol ~85.7% = options are pricing elevated uncertainty.
Near-term IV trend: IV 30d is well below the 5D/10D IV averages shown (254/273), implying volatility has been coming down (less “panic premium” than recently).
Liquidity/flow: Today vs 30D avg volume 50 (still small absolute), and OI is modest (2,959 total), so options may not reliably reflect broad institutional conviction.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
can trigger short-covering / mean-reversion bounces.
Neutral/Negative Catalysts
Fundamentals recently weakened materially (revenue down sharply YoY), which can keep pressure on the equity despite one-time cash proceeds.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: $19.55M, down 56.52% YoY (major top-line contraction).
Profitability: Net income improved YoY (loss narrowed) to -34.69M (+28.77% YoY improvement), and EPS improved to -0.09 (+28.57% YoY improvement), but the company remains loss-making.
Margins: Gross margin 48.51%, down 6.22% YoY, indicating weaker unit economics vs last year.
Overall: Cost/earnings losses are improving, but the growth trend is negative on revenue, which typically caps upside unless guidance/forward demand improves.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analyst rating/price target change data was not provided, so a confirmed recent trend cannot be stated.
Wall Street-style pros: monetizing an asset (SomaLogic) for cash strengthens liquidity/runway; potential strategic refocus.
Wall Street-style cons: sharp revenue decline and ongoing losses; small-cap/low-price profile can imply higher dilution/financing overhang risk; technical trend remains bearish, which often keeps analysts cautious until execution improves.
Notable trading by politicians/influential figures: no recent congress trading data available; hedge fund and insider activity described as neutral (no significant recent trend).
Wall Street analysts forecast LAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is 1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is 1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
Current: 1.240
Low
1.35
Averages
1.35
High
1.35
Current: 1.240
Low
1.35
Averages
1.35
High
1.35
TD Cowen
Hold
downgrade
AI Analysis
2025-11-05
Reason
TD Cowen
Price Target
AI Analysis
2025-11-05
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Standard BioTools to $1.35 from $1.55 and keeps a Hold rating on the shares. The firm said there were no surprises in the print with the company now reporting continuing operations revenue post the announced sale of SomaLogic.
TD Cowen
Buy
to
Hold
downgrade
2025-08-13
Reason
TD Cowen
Price Target
2025-08-13
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded Standard BioTools to Hold from Buy with a price target of $1.55, down from $1.60, post the Q2 report. The company sees a lower growth outlook for the core business and less visibility following the sale of SomaLogic. The company's core business trends will continue to be challenged amid macro headwinds, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LAB
